151751-Najiba-Chargi

310 CHAPTER 16 28. Heymsfield SB, Wang Z, Baumgartner RN, Ross R. Human body composition: Advanc - es in models and methods. Annu Rev Nutr. 1997;17:527-558. doi: 10.1146/annurev. nutr.17.1.527 [doi]. 29. Williams BA, Mandrekar JA, Mandrekar SJ, Cha SS. Finding optimal cutpoints for con - tinuous covariates with binary and time-to- event outcomes. Furth AF. 2006. :MN. 30. Carneiro IP, Mazurak VC, Prado CM. Clini - cal implications of sarcopenic obesity in cancer. Curr Oncol Rep. 2016;18(10):5. doi: 10.1007/s11912-016-0546-5 [doi]. 31. Baracos VE, Arribas L. Sarcopenic obesity: Hidden muscle wasting and its impact for survival and complications of cancer ther- apy. Ann Oncol. 2018;29(suppl_2):ii9. doi: 10.1093/annonc/mdx810 [doi]. 32. Palmela C, Velho S, Agostinho L, et al. Body composition as a prognostic factor of neoadjuvant chemotherapy toxicity and outcome in patients with locally ad- vanced gastric cancer. J Gastric Cancer. 2017;17(1):74-87. doi: 10.5230/jgc.2017.17. e8 [doi]. 33. Sjoblom B, Benth JS, Gronberg BH, et al. Drug dose per kilogram lean body mass predicts hematologic toxicity from car- boplatin-doublet chemotherapy in ad- vanced non-small-cell lung cancer. Clin Lung Cancer. 2017;18(2):e136. doi: S1525- 7304(16)30234-0 [pii]. 34. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemo- therapy toxicity and time to tumor pro- gression in metastatic breast cancer pa- tients receiving capecitabine treatment. Clin Cancer Res. 2009;15(8):2920-2926. doi: 10.1158/1078-0432.CCR-08-2242 [doi]. 35. Chargi N, Bril SI, Emmelot-Vonk MH, de Bree R. Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer. Eur Arch Otorhi - nolaryngol. 2019;276(5):1475-1486. doi: 10.1007/s00405-019-05361-4 [doi].